Neurocrine Biosciences (NBIX) said it has obtained exclusive rights for all indications to develop and commercialize osavampator for patients with inadequate response to treatment of major depressive disorder following an amended agreement with Takeda Pharmaceuticals.
The rights are for all territories worldwide, except Japan, where Takeda will reacquire exclusive rights, according to a statement late Monday. Each company is responsible for development costs in their respective region, and both companies are eligible to receive royalty payments.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。